Jeannie T. Lee, MD, PhD, is a Professor of Genetics (and Pathology) at Harvard Medical School, and is Vice Chair of the Department of Molecular Biology at the Massachusetts General Hospital. Dr. Lee specializes in the study of epigenetic regulation by long noncoding RNAs and uses X-chromosome inactivation as a model system. Dr. Lee also actively translates basic knowledge to treat human diseases. She cofounded Translate Bio and Fulcrum Therapeutics and also serves as an Advisor to Skyhawk Therapeutics. She is a Member of the National Academy of Sciences, a Harrington Rare Disease Scholar of the Harrington Discovery Institute, a recipient of the Lurie Prize from the Foundation for the National Institutes of Health, an awardee of the Centennial Prize from the Genetics Society of America, the 2010 Molecular Biology Prize and the 2020 Cozzarelli Prize from the National Academy of Sciences, U.S.A, and a Fellow of the American Association for the Advancement of Science. Dr. Lee was also named a Distinguished Graduate of the University of Pennsylvania School of Medicine and an Investigator of the Howard Hughes Medical Institute. From 2013-2018, she co-launched the Epigenetics Initiative at Harvard Medical School and served as its Co-Director. Serving on the Board of Directors of the Genetics Society of America (GSA), Dr. Lee spearheaded the TAGC (The All-Genetics) Conference in 2016. As GSA’s President, Dr. Lee established a Strategic Plan and a Development strategy for the society in 2018. She received her A.B. in Biochemistry and Molecular Biology from Harvard University, obtained M.D.-Ph.D degrees from the University of Pennsylvania School of Medicine, and carried out post-graduate work at MGH and the Whitehead Institute/MIT.
This speaker appears at this event:
- Disruptive Dozen: 12 Technologies That Will Reinvent GCT in the Next Five Years
- RNA Therapeutics | Lessons Learned
This speaker appeared in 2021
Jeannie Lee, MD, PhD
Molecular Biologist, MGH
Professor of Genetics, HMS